Interleukin‐10 promoter polymorphisms and haplotypes in patients with Guillain–Barré syndrome
Annals of Clinical and Translational Neurology · 2024
DOI: 10.1002/acn3.51939 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Shoma Hayat und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Gut-Brain Axis, Infectious Diseases Division (IDD), icddr,b, Dhaka, Bangladesh. Hauptthemen laut MEDLINE: Guillain-Barre Syndrome, Interleukin-10. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Interleukin‐10 (IL‐10) is a multifunctional cytokine that exerts both pro‐ and anti‐inflammatory effects on the immune system as well as in the pathogenesis of Guillain–Barré syndrome (GBS). We investigated whether the three common polymorphisms ‐1082 G/A(rs1800896), ‐819 C/T(rs1800871), and ‐592 C/A(rs1800872) in the promoter region of IL‐10 have any influence on the susceptibility, severity, and clinical outcome of GBS.
Methods
IL‐10 promoter polymorphisms were investigated in 152 patients with GBS and 152 healthy controls from Bangladesh using polymerase chain reaction and restriction fragment length polymorphism (PCR‐RFLP), and allele‐specific oligonucleotide‐PCR (ASO‐PCR). Haplotype patterns and frequencies were analyzed using Heatmaply R‐package, chi‐square, and Fisher's exact test. The serum level of IL‐10 was measured through enzyme‐linked immunosorbent assays. p ‐values < 0.05 were considered statistically significant.
Results
IL‐10 promoter polymorphisms ‐1082 G/A, ‐819 C/T, and ‐592 C/A were not associated with GBS susceptibility. The homozygous ‐819 TT genotype showed a tendency with susceptibility ( p = 0.029; p c = 0.08) and was prevalent in axonal variants of GBS compared to demyelinating subtypes and controls ( p = 0.042, OR = 8.67, 95% CI = 1.03–72.97; p c = 0.123 and p = 0.005, OR = 4.2, 95% CI = 1.55–11.40; p c = 0.015, respectively). Haplotype analysis revealed 19 patterns of genotypes and high IL‐10 expression haplotype combinations (GCC/GTA, GCC/ATA, and GCC/GCA) may have influence on disease severity ( p = 0.026; p c = 0.078). Serum expression of IL‐10 was elevated in GBS patients ([GBS, 12.16 ± 45.71] vs. [HC, 0.65 ± 5.17] pg/mL; p = 0.0027) and varied with disease severity ([severe‐GBS, 15.25 ± 51.72] vs. [mild‐GBS, 3.59 ± 19.79] pg/mL, p = 0.046).
Interpretation
The ‐819 TT genotypes influence axonal GBS, and high frequency of IL‐10 expression haplotype combination with elevated serum IL‐10 may play an important role in disease severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Gut-Brain Axis, Infectious Diseases Division (IDD), icddr,b, Dhaka, Bangladesh.
- Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh.
- National Institute of Neurosciences and Hospital, Dhaka, Bangladesh.
ORCID-Profile: Shoma Hayat, Asaduzzaman Asad, Md Abu Jaher Nayeem, Md Golam Mostafa, Zhahirul Islam
Zitieren
APA
Hayat, S., Asad, A., Munni, M. A., Nayeem, M. A. J., Mostafa, M. G., Jahan, I., Howlader, M. Z. H., Mohammad, Q. D., & Islam, Z. (2024). Interleukin‐10 promoter polymorphisms and haplotypes in patients with Guillain–Barré syndrome. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.51939
Vancouver
Hayat S, Asad A, Munni MA, Nayeem MAJ, Mostafa MG, Jahan I, et al. Interleukin‐10 promoter polymorphisms and haplotypes in patients with Guillain–Barré syndrome. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.51939
BibTeX
@article{Hayat2024,
author = {Hayat, Shoma and Asad, Asaduzzaman and Munni, Moriam Akter and Nayeem, Md Abu Jaher and Mostafa, Md Golam and Jahan, Israt and Howlader, Md Zakir Hossain and Mohammad, Quazi Deen and Islam, Zhahirul},
title = {Interleukin‐10 promoter polymorphisms and haplotypes in patients with Guillain–Barré syndrome},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
doi = {10.1002/acn3.51939}
}
EUVIMED